All In Biotech

Drug Trial Radar · NCT07639021

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 233 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

233

Actual

Start

Jun 9, 2026

Primary completion

Jun 14, 2027

Study completion Jun 14, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Conditions

  • Obesity

Interventions

  • NNC0662-0419Drug

    NNC0662-0419 will be administered subcutaneously.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously.

  • NNC0662-0419 PlaceboDrug

    Placebo matched to NNC0662-0419 will be administered subcutaneously.

  • Semaglutide placeboDrug

    Placebo matched to semaglutide will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of gastrointestinal adverse eventsTime frame: From week 0 to week 39

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama

  • FDRC

    Costa Mesa, California

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California

  • Encore Medical Research LLC

    Hollywood, Florida

  • South Broward Research LLC

    Miramar, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Midwest Inst For Clin Res

    Indianapolis, Indiana

  • L-MARC Research Center

    Louisville, Kentucky

  • Endo And Metab Cons

    Rockville, Maryland

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Great Lakes Medical Research

    Westfield, New York

  • KDCILM, LLC & Accellacare US, Inc.

    Wilmington, North Carolina

  • Family Practice Center of Wadsworth Inc.

    Wadsworth, Ohio

  • UPA Ctr Weight and Eating Dis

    Philadelphia, Pennsylvania

  • Clinical Res Collaborative

    Cumberland, Rhode Island

  • Holston Medical Group_Bristol

    Bristol, Tennessee

  • Holston Medical Group

    Kingsport, Tennessee

  • Clinical Research Associates

    Nashville, Tennessee

  • PlanIt Research, PLLC

    Houston, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • National Clin Res Inc.

    Richmond, Virginia

  • Rainier Clin Res Ctr Inc

    Renton, Washington

  • Isis Clinical Res. Ctr P.S.C.

    Guaynabo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.